The circadian clock imposes daily rhythms in cell proliferation, metabolism, inflammation and DNA damage response 1,2 . Perturbations of these processes are hallmarks of cancer 3 and chronic circadian rhythm disruption predisposes individuals to tumour development 1,4 . This raises the hypothesis that pharmacological modulation of the circadian machinery may be an effective therapeutic strategy for combating cancer. REV-ERBs, the nuclear hormone receptors REV-ERBα (also known as NR1D1) and REV-ERBβ (also known as NR1D2), are essential components of the circadian clock 5,6 . Here we show that two agonists of REV-ERBs-SR9009 and SR9011-are specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and have no effect on the viability of normal cells or tissues. The anticancer activity of SR9009 and SR9011 affects a number of oncogenic drivers (such as HRAS, BRAF, PIK3CA and others) and persists in the absence of p53 and under hypoxic conditions. The regulation of autophagy and de novo lipogenesis by SR9009 and SR9011 has a critical role in evoking an apoptotic response in malignant cells. Notably, the selective anticancer properties of these REV-ERB agonists impair glioblastoma growth in vivo and improve survival without causing overt toxicity in mice. These results indicate that pharmacological modulation of circadian regulators is an effective antitumour strategy, identifying a class of anticancer agents with a wide therapeutic window. We propose that REV-ERB agonists are inhibitors of autophagy and de novo lipogenesis, with selective activity towards malignant and benign neoplasms.
), but have little or no toxic effect on normal cells at comparable concentrations ( Fig. 1a, b , Extended Data Fig. 1a, b) . Therefore, the antitumour activity of REV-ERB agonists is not limited to a single oncogenic driver, but is instead effective against a broad spectrum of tumorigenic pathways.
Levels of REV-ERB mRNA are comparable between normal cells and their transformed counterparts (Fig. 1c ). The anticancer activity of SR9009 and SR9011 is abolished following the downregulation of REV-ERBs by multiple short hairpin RNAs (shRNAs) ( Fig. 1o , p, Extended Data Fig. 1d, l) .
The impairment of cancer cell viability on treatment with SR9009 and SR9011 is due to induction of apoptosis, as assessed by cleaved caspase 3 and terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labelling (TUNEL) assays and further verified by electron microscopy (Fig. 1e , f, h, i, k, l, Extended Data Fig. 1g-k) . As the tumour suppressor p53 has an important role in apoptosis and is often inactivated in cancer, we tested whether the induction of apoptosis by agonists of REV-ERBs requires p53. Agonist-induced apoptosis was largely intact in cells with compromised p53 function (mutation, deletion or shRNA-mediated downregulation; Fig. 1a , b, Extended Data Fig. 2a-j) , which indicates that the downstream apoptosis trigger is independent of p53. Agonists of REV-ERBs do not, therefore, require the presence of wild-type p53 and are effective against several oncogenic pathways; these observations expand the potential therapeutic repertoire of agonists of REV-ERBs against multiple tumour types.
The selectivity of agonists of REV-ERBs towards cancer cells suggests that SR9009 and SR9011 may affect cellular processes that are critical specifically for the survival of tumour cells, and not essential for normal cells. The increased production of reactive oxygen species (ROS) is detrimental specifically to cancer cells 17 , insofar as normal cells exhibit a greater tolerance for increased ROS production than do cancer cells. Agonists of REV-ERBs and other circadian clock components regulate mitochondrial metabolism and its oxidative activity 15, 18 . If ROS overproduction is involved in the enhanced sensitivity of cancer cells to agonists of REV-ERBs, lowering oxidative stress would protect them against the agonists. We co-treated cancer cells with agonists of REV-ERBs and the antioxidant N-acetyl-l-cysteine (NAC). As a second way of lowering oxidative stress, we administered agonists of REV-ERBs under hypoxic conditions. In neither experimental setting was the ability of agonists of REV-ERBs to trigger apoptosis in cancer cells impaired (Extended Data Figs 2k-n, 3) , which suggests that excessive ROS production is not involved in the enhanced sensitivity of cancer cells to these agonists.
Next we investigated whether agonists of REV-ERBs target anabolic pathways that are selectively critical for cancer cell survival. REV-ERBs tightly control lipid metabolism by repressing several lipogenic enzymes, including fatty acid synthase (FAS) and stearoyl-CoA Letter reSeArCH desaturase 1 (SCD1) 14 . Unlike normal cells, cancer cells are highly dependent on de novo lipogenesis; major efforts are underway to develop cancer therapeutics on the basis of specific inhibitors of FAS and SCD1 19 . Agonists of REV-ERBs strongly reduced both mRNA and protein expression of these two key rate-limiting enzymes, which are involved in de novo lipogenesis (Extended Data Fig. 4a, b ). This reduction led to the perturbation of several fatty acids and phospholipids (Extended Data Fig. 4c -i). Because oleic acid is the final product of SCD1 (Extended Data Fig. 4j ), we investigated whether supplementing culture medium with oleic acid could attenuate the anticancer activity of agonists of REV-ERBs. Oleic acid impaired the anticancer activity of REV-ERB agonists (Extended Data Fig. 4k ) but did not completely abrogate cytotoxicity, which suggests the involvement of additional mechanisms. By contrast, palmitic acid supplementation did not confer any protection (Extended Data Fig. 4l ).
Cancer cells deal with their high metabolic demands through complex metabolic rewiring that involves the hyperactivation of autophagy 20 . Autophagy is essential for cancer cell survival, whereas normal cells depend on this catabolic cellular process only in starvation conditions 20 . Accordingly, inhibition of autophagy is a promising therapeutic strategy. However, chloroquine and its derivatives, which are the most common autophagy inhibitors, lack specificity and are toxic at high doses, potentially limiting their utility in clinical settings 21 .
Autophagy is modulated in a circadian fashion and is controlled by NR1D1 15, 22 . These observations prompted us to investigate whether the inhibition of autophagy is involved in the anticancer activity of agonists of REV-ERBs. We initially analysed the autophagosome marker LC3B to investigate whether agonists of REV-ERBs affect the numbers of autophagosomes; both SR9009 and SR9011 reduced the number of autophagosomes ( Fig. 2a, b , Extended Data Fig. 5a, b ). This decrease in autophagosomes suggests that the administration of agonists of REV-ERBs inhibited autophagy. To expand upon this observation, we tested whether p62 (also known as sequestosome-1), which is a protein that is specifically degraded by autophagy, accumulates following treatment with agonists of REV-ERBs. These agonists induced a marked accumulation of p62 in a range of cancer cell lines. ( Fig. 2c -e, Extended Data Fig. 5c-e ). If autophagy has a dominant role in the induction of apoptosis triggered by agonists of REV-ERBs, autophagy inhibition should precede apoptosis induction: indeed, the blockage of autophagy shown by p62 accumulation occurred before the induction of apoptosis ( Fig. 2f , g, Extended Data Fig. 5f , g). The inhibition of autophagy was further confirmed by analysis of the autophagic flux and by electron microscopy, with the latter showing that autophagosome formation was also impaired on starvation (Extended Data Fig. 6a-c ). In addition, treatment with agonists of REV-ERBs prevented lysosome turnover, as shown by an increase in the lysosomal protein LAMP1 and by the enhanced activity of LysoTracker Red, which stains acidic vesicles (Extended Data Fig. 6d, e ). The accumulation of lysosomes was also observed by transmission electron microscopy (Extended Data Fig. 6f ). Together, these results indicate that agonists of REV-ERBs potently inhibit autophagy.
When challenged with starvation, cancer cells are extremely sensitive to the inhibition of autophagy. The cytotoxicity of SR9009 and SR9011 was enhanced by starvation in a range of cancer cell lines ( Fig. 2h , Extended Data Fig. 6g , h), which indicates the involvement of autophagy inhibition. Starvation did not induce the expression of REV-ERBs (Extended Data Fig. 6i, j) , showing that autophagy inhibition is responsible for the increased sensitivity to agonists of REV-ERBs in starved cancer cells. Finally, the overexpression of core autophagy genes (ULK2, ULK3 and LKB1 (also known as STK11) abrogated Figure 1 | SR9009 is selectively lethal in cancer cell lines driven by different oncogenic signalling. a, SR9009 treatment is cytotoxic specifically in cancer cells (72 h). One-way ANOVA. n indicates biological replicates: astrocytes, n = 12 (mock), n = 12 (2.5 μ M), n = 12 (5 μ M), n = 15 (10 μ M), n = 18 (20 μ M); astrocytomas, n = 8 (mock), n = 9 (2.5 μ M), n = 10 (5 μ M), n = 11 (10 μ M) and n = 6 (20 μ M), * P = 0.037; and brain-tumour-initiating cells (BTICs), n = 10 (mock), n = 9 (2.5 μ M), n = 9 (5 μ M), n = 15 (10 μ M) and n = 18 (20 μ M), * ***P < 0.0001. b, SR9009 treatment impairs the viability of BJ-ELR, but not BJ, cells (proliferation assay, 7 days, 20 μ M). LT/ST, large T antigen, small T antigen. c, Expression of REV-ERBs in BJ and BJ-ELR cells; quantitative PCR with reverse transcription (qRT-PCR), n = 3 biologically independent samples, two-tailed Mann-Whitney test. Expression of mRNA shown relative to housekeeper RPLP0. d, Jurkat cell viability is reduced by SR9009; n = 12 biological replicates, 72 h 20 μ M, one-tailed Mann-Whitney test, ****P < 0.0001. e, f, Immunostaining (e) and quantification (f) of cleaved caspase 3 (Cl. Casp. 3) and TUNEL assays (72 h, 20 μ M); in f, n = 5 (mock) and 6 (SR9009) biologically independent samples, one-tailed Mann-Whitney test, cleaved caspase 3 assay, * * P = 0.0022; TUNEL assay, * * P = 0.0022. g, Breast cancer cell line MCF-7 viability is reduced by SR9009; n = 12 (mock) or 8 (SR9009) biological replicates, 72 h 20 μ M, one-tailed Mann-Whitney test, ****P < 0.0001. h, i, Immunostaining (h) and quantification (i) of cleaved caspase 3 and TUNEL assays (72 h, 20 μ M). In i, n = 5 biologically independent samples, one-tailed Mann-Whitney test; cleaved caspase 3 assay, * * P = 0.004; TUNEL assay, * * P = 0.004. j, Colon cancer cell line HCT116 viability is reduced by SR9009; n = 8 biological replicates, water-soluble tetrazolium salt (WST-1) assay, 72 h, one-tailed Mann-Whitney test, ****P < 0.0001. k, l, Induction of apoptosis is shown by cleaved caspase 3 and TUNEL staining (k, 72 h, 20 μ M); for quantification in l, n = 8 (mock) or 5 (SR9009) biologically independent samples, one-tailed Mann-Whitney test; cleaved caspase 3 assay, * * * P = 0.0008; TUNEL assay * * P = 0.0021. m-o, Prolonged SR9009 treatment eradicates cancer cells (7 days, 20 μ M), but does not affect cells that express NR1D1 and NR1D2 shRNA. shNS, non-silencing shRNA. p, NR1D1 and NR1D2 qRT-PCR; n = 4 biologically independent samples; one-tailed Mann-Whitney test, * P = 0.0286. NS, not significant. AU, arbitrary unit, shREV-ERBs, NR1D1 and NR1D2 shRNA. Scale bars, 50 μ m. All panels representative of three biologically independent experiments. Data are mean ± s.e.m., except c, mean ± s.d.
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induction of apoptosis in various tumour cell lines ( Fig. 2i -k, Extended Data Fig. 6k -p).
Next, we sought to determine how agonists of REV-ERBs block autophagy. We initially compared differential autophagy outcomes observed between chloroquine and agonists of REV-ERBs. Chloroquine inhibits autophagy at a late stage by blocking the fusion of autophagosomes and lysosomes, and thereby leads to the accumulation of autophagosomes (Extended Data Fig. 6a -c). By contrast, agonists of REV-ERBs decreased the number of autophagosomes, which suggests that they block autophagy at an early stage.
To gain additional mechanistic insights, we investigated whether agonists of REV-ERBs can regulate the expression of core autophagy genes. Analysis of a published report 5 on chromatin occupancy of REV-ERBs revealed the presence of peaks in Ulk3, Ulk1, Becn1 and Atg7 (Extended Data Fig. 7a ). Using HOMER software (http://homer. ucsd.edu/homer/), we found that NR1D1 and NR1D2 consensus binding sites were also present within these genetic loci (Extended Data Fig. 7b-e ). Accordingly, ULK3, ULK1, BECN1 and ATG7 mRNAs and protein levels of ULK3, ULK1, BECN1 and ATG7 were downregulated on treatment with agonists of REV-ERBs, whereas the expression of these genes was induced following depletion of REV-ERBs by shRNA (Extended Data Figs 7f-j, 8a-e). Furthermore, in REV-ERB-depleted cells, agonists of REV-ERBs did not repress autophagy genes (Extended Data Figs 7k, 8f).
The activation of aberrant oncogenic stimuli is an early step in tumorigenesis. Oncogene-induced senescence (OIS) arises in normal cells to limit the expansion of cells affected by oncogenic stress 23, 24 . Although this provides an immediate benefit by arresting potentially dangerous cells, the accumulation of senescent cells over long periods of time contributes to tumour formation, tumour progression and age-related diseases 25 . Furthermore, the induction of cellular senescence upon anticancer chemotherapy treatment promotes chemotherapy resistance and generates an environment that may support uncontrolled growth of neighbouring cells and fuel relapse 25 ; this highlights the need for senolytic agents. Although de novo lipogenesis is upregulated in cancer cells but not in OIS cells 26 , an elevated level of autophagy is a known characteristic of OIS cells 27 . Agonists of REV-ERBs are lethal when administered to cells characterized by oncogenic RAS signalling ( Fig. 1 , Extended Data Fig. 1 ), affect slowly proliferating cancer stem cells and potently inhibit autophagy ( Fig. 2 , Extended Data Figs 5, 6, 8g-l).
We investigated whether treatment of OIS cells with agonists of REV-ERBs would block autophagy and lead to apoptosis. The overexpression of the HRAS proto-oncogene GTPase with the oncogenic mutation G12V (HRAS G12V ) (Extended Data Fig. 9a ) established OIS, as shown by an increase in senescence-associated β -galactosidase activity and by upregulation of cell-cycle inhibitors (Extended Data Fig. 9b , c). Notably, agonists of REV-ERBs triggered the induction of apoptosis in OIS cells without affecting normal proliferating or quiescent cells ( Fig. 3a -c, Extended Data Fig. 9d -g). In agreement with previous results ( Fig. 2c -e, Extended Data Fig. 5c -e), treatment with agonists of REV-ERBs led to the accumulation of p62 and lysosomes and a reduction in autophagosomes ( Fig. 3d , e, Extended Data Fig. 9h , i). Therefore, agonists of REV-ERBs inhibit autophagy in OIS cells. Finally, on overexpression of ULK3, the pro-apoptotic ability of the agonists of REV-ERBs was impaired ( Fig. 3f ). These results show that through their ability to block autophagy, these agonists can target a premalignant non-proliferating cellular population. Therefore, agonists of REV-ERBs display senolytic activity in addition to their oncolytic effects.
To understand whether agonists of REV-ERBs represent an effective therapeutic strategy, we investigated whether agonists of REV-ERBs affect OIS and tumour viability in vivo. Naevi are benign lesions consisting of cutaneous melanocytes that have undergone OIS upon aberrant activation of RAS signalling 28 . Consistent with the in vitro observations discussed earlier, SR9009 treatment led to an increase in apoptosis in NRAS-induced naevi in mice, and the repression of autophagy genes ( Fig. 4a -c, Extended Data Fig. 10a ). This indicates the potential for non-proliferating premalignant cells to be selectively targeted by agonists of REV-ERBs in vivo. However, although naevi have been used as a model for studying OIS in vivo 28 , they do not Letter reSeArCH affect neighbouring tissues and do not develop into melanomas: further studies are necessary to assess the therapeutic relevance of agonists of REV-ERBs as senolytic tools 25, 29 . As previously reported 14, 15 , agonists of REV-ERBs do not show overt toxicity; our TUNEL analysesperformed in normal skin and brain tissues-and our body weight analyses confirm this finding (Extended Data Fig. 10b-d ). By contrast, established anticancer agents such as temozolomide are characterized by several side effects (Extended Data Fig. 10d ).
SR9009 is known to cross the blood-brain barrier 14 , and several glioblastoma cell lines-including brain-tumour initiating cells (005 and RIGH), A172 and glioblastoma stem cells derived from patients-are sensitive to treatment with agonists of REV-ERBs in vitro ( Fig. 1a , Extended Data Figs 1a, 2f, g, 8g and 10e). On analysis of REV-ERB status in glioblastoma data from The Cancer Genome Atlas (http:// www.cbioportal.org/) 30, 31 , we observed that NR1D1 and NR1D2 status was unaltered in nearly all patients with glioblastoma (Extended Data Fig. 10f , and data not shown), which suggests a possible therapeutic use for agonists of REV-ERBs in clinical settings.
Finally, NR1D2 expression was positively correlated with survival in brain cancer patients ( Fig. 4d , NR1D1 data are not available). For the above reasons, and because of the low toxicity of agonists of REV-ERBs, we tested SR9009 for treating brain tumours. Brain-tumour-initiating cells were transplanted into mouse brains by stereotaxic injection, and on tumour establishment, SR9009 treatment was initiated. SR9009 reduced glioblastoma growth, triggered apoptosis and downregulated the expression of autophagy genes ( Fig. 4e -i, Extended Data Fig. 10g ). Additionally, SR9009 reduced tumour growth in a xenograft model of a patient-derived glioblastoma (Extended Data Fig. 10h , i). Most notably, SR9009 effectively and significantly improved survival in two glioblastoma models, including a xenograft derived from a patient ( Fig. 4j, Extended Data Fig. 10j ). The anticancer activity of SR9009 was Letter reSeArCH similar to that of temozolomide, the current therapeutic standard for glioblastoma (Extended Data Fig. 10j ). Unlike temozolomide, however, SR9009 lacked toxicity.
Together, these results indicate that agonists of REV-ERBs are pharmacological tools that target a potentially wide spectrum of tumours and therapeutic windows, are highly selective and exhibit low toxicity (Fig. 4k) . Importantly, REV-ERB agonists selectively target slowly proliferating tumorigenic and premalignant populations, such as naevi (Fig. 4k ). We propose that the anticancer activity of agonists of REV-ERBs involves the inactivation of at least two cancer hallmarks 3 : de novo lipogenesis and autophagy, with autophagy-given its importance in meeting the metabolic demands of cancer cells-possibly having a major role. By simultaneously targeting two essential cancer hallmarks, agonists of REV-ERBs may represent an improved therapeutic strategy for treating cancer. These results strongly indicate that pharmacological modulation of circadian machinery is an innovative and selective strategy for cancer treatment (Fig. 4k ).

MethOdS
Cell culture and treatments. BJ, WI38, BJ-ELR, A375, Jurkat, MCF7, T47D, HCT116, Becker (astrocytoma line, JCRB Cell Bank), PANC-1 and SK-MEL28 cells were grown under standard tissue-culture conditions and obtained through ATCC. No further authentication was performed. HCT116 p53 −/− cells were a gift from B. Amati. BTICs (005, RIGH) were cultured as previously described 32 . OIS cells were generated as previously described 33 . Quiescent cells were obtained by contact inhibition. Cell lines were tested for mycoplasma contamination. Senescence-associated (SA)-β -galactosidase assay (Cell Biolabs) was performed as previously described 33 . SR9009 (Xcessbio, Millipore) and SR9011 (Xcessbio) were dissolved in DMSO for in vitro studies and for ear topical administration; SR9009 and temozolomide (Cayman Chemicals) were dissolved in 15% Cremophor (Sigma-Aldrich) in sterile water for in vivo studies. Hypoxia was induced by lowering incubator oxygen percentage to 1-2%, or with NAC supplementation in the medium (10 mM; Sigma-Aldrich); EBSS (Life Technologies) was used to induce starvation. Proliferation assays were performed to assess the cytotoxicity of SR9009 and SR9011 in normal and cancer cells by using crystal violet and cell proliferation reagent WST-1 (Roche); all treatment started when cells were 80% confluent (except for the BTIC experiments). MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium) assays were performed according to the manufacturer's instructions (CellTiter 96 Aqueous One, Promega). Human samples. Glioblastoma stem cells (GSCs) were isolated from specimens from patients with glioblastoma, who had undergone surgery at the University of Texas MD Anderson Cancer Center (UTMDACC) 34 . The diagnosis of glioblastoma was established by histological examination, according to the WHO (World Health Organization) classification. Samples derived from patients were obtained with the consent of patients, under an ethically approved Institutional Review Board protocol LAB04-0001 chaired by F. F. Lang (UTMDACC). Tumour specimens were dissociated and resuspended in Dulbecco's modified Eagle's medium/F12 (Gibco) supplemented with B27 (× 1, Invitrogen), bFGF (20 ng ml −1 Peprotech), and EGF (20 ng ml −1 , Peprotech). Cells were cultured as neurospheres and passaged every 5-7 days, on the basis of sphere size. Plasmids. pBABE-Puro and pBABE-Puro H-RasV12 were used as previously described 33 . pLKO.1 NR1D1 shRNA (shNR1D1), pLKO.1 NR1D2 shRNA (shNR1D2) (Sigma-Aldrich), pLPCULK3, pLPCLC3B (gift from the Narita laboratory) pLenti-ULK2 (ABM), pBABE-LKB1 (gift from the Shaw laboratory) were obtained as indicated. shNR1D1 no. 1 : C CG GG CG CT TT GC TT CG TT G T TC AA CT CG AG TT GA AC AA CGAAGCAAAGCGCTTTTT; s hN R1 D1 no. 2: C C G GC CA GC CC TG AA TC CC TC TA TA CT CG AG TA TA GA GG GATTCAGGGCTG GTTTTT; shNR1D2 no. 1: CCGGGCCCTCCAACTTAGTGATGAACTC GAGTTCATCACTAAGTTGGAGGGCTTTTT; shNR1D2 no. 2 : C CG GCCAGT ACAAGAAGTGCCTGAACTCGAGTTCAGGCACTTCTTGTACTGGTTTTT. Immunofluorescence microscopy. For brain-tissue immunofluorescence, all mice were perfused with 0.9% NaCl followed by 4% paraformaldehyde in PBS. The brains were collected, fixed overnight and transferred to 30% sucrose in PBS. For fluorescent staining, 40-μ m coronal sections on a sliding microtome were prepared and imaged with the Zeiss LSM 780 Side Port Laser Scanning Confocal microscope. Mouse ears were fixed in 4% paraformaldehyde and subjected to histology. Paraffin-embedded sections were stained with anti-TRP2 at 2 μ g ml −1 (Santa Cruz), TUNEL In Situ Cell Death Detection Kit, Fluorescein (Roche). Cells were fixed and probed as previously described 33 . Images and confocal sections were acquired using the Zeiss LSM 780 Side Port Laser Scanning Confocal microscope. Comparative immunofluorescence microscopy analyses were performed in parallel, with identical acquisition and analysis parameters. ImageJ software (v1.49g) was used to perform quantitative analyses and to assay intensity differences. To count LC3B puncta, after selecting a threshold to minimize any effect of background signal analyses were performed on projected stack using the ImageJ function 'analyse particles' . 3D Objects Counter was used to analyse intensity. Apoptosis was evaluated by the immunostaining of cleaved caspase 3 (Cell Signaling No. 9664 1:200), and by TUNEL assay using In Situ Cell Death Detection Kit, Fluorescein or TMR red (Roche). Antibodies used were LC3B (Cell Signaling No. 3868 1:200), Lamp1 (Cell Signaling #9091 1:200), Sqstm1/p62 (Abcam ab56416 1:100), Sqstm1/p62 (MBL PM045) and Ras (BD #610002, 1:200). LysoTracker Red DND-99 (Lifetech) was used to visualize lysosomes. Electron microscopy. Cells grown on ACLAR coverslips were fixed in 2.5% glutaraldehyde with 2% paraformaldehyde in 0.15 M cacodylate buffer containing 2 mM calcium chloride, pH 7.4, at 37 °C for five minutes, followed by an hour at 4 °C. The coverslips were then washed in 0.15 M cacodylate buffer containing 2 mM calcium chloride, and secondarily fixed in 1% osmium tetroxide and 0.3% potassium ferrocyanide in the same buffer. Subsequently, the coverslips were washed in water and stained en bloc with 2% uranyl acetate, followed by a graded dehydration in ethanol (35%, 50%, 70%, 90%, 100% and 100%). Samples were then rapidly infiltrated in EPON resin using a Pelco BioWave microwave processing unit (Ted Pella), flat embedded and cured at 60 °C overnight. Regions of interest were excised and remounted on blank resin stubs. Ultrathin (70 nm) sections were then cut on a UC7 ultramicrotome (Leica) and cells were imaged on a transmission electron microscope at 120 kV (Zeiss Libra 120 PLUS). Immunoblotting. Cells were lysed in sample buffer and 20-50 μ g of whole cell lysate was resolved by gel electrophoresis (Bolt 4-12% Bis-Tris Plus Gels, Life Technologies), transferred to nitrocellulose (iBlot Transfer Stack, nitrocellulose, Life Technologies) and probed with the following antibodies: anti-cleaved caspase 3 (1:250 Cell Signaling No. 9664); anti-vinculin clone hVIN-1 (SIGMA; 1:10,000), anti Sqstm1/p62 (Abcam ab56416; 1:500), BECN1 (Santacruz H-300, sc-11427; 1:250), ATG7 (Sigma-Aldrich, A2856; 1:1,000), ULK1 (Sigma-Aldrich, A7481; 1:250), ULK3 (Sigma-Aldrich, SAB4200132; 1:500), SCD1 (Abcam, ab19862; 1:1,000), FASN (Cell Signaling, 3180; 1:1,000) and Tubulin (Millipore, 05-829; 1:5,000). qRT-PCR. Total RNA was extracted from cells and tissues using RNAeasy (Qiagen) according to the manufacturer's instructions, and treated with DNase before reverse transcription. cDNA was generated using qScript cDNA SuperMix (Quanta BioSciences). The cDNA was used as a template in real-time quantitative PCR reactions with specific primers on an ABI 7900HT Fast Real-Time PCR System. The reactions were prepared using SyBR Green reaction mix from Roche. The gene (RPLP0) encoding ribosomal protein P0 (RPP0) was used as a control for normalization. Human primer sequences for qRT-PCR: RPLP0-fw,
CDKN2A-fw, 5′ -CCCAACGCACCGAATAGTTAC-3′ ; CDKN2A-rev, ATTCCA ATTCCCCTGCAAACT-3′ ; SCD1-fw, 5′ -GACGATGAGCTCCTGCTGTT-3′ ; SCD1-rev, 5′ -CTCTGCTACACTTGGGAGCC-3′ ; FASN-fw, 5′ -CATCGGCTCC ACCAAGTC-3′; FASN-rev, 5′ -GCTATGGAAGTGCAGGTTGG-3′ ; Mouse primer sequences for qRT-PCR: ulk1-fw, 5′ -GAGCCGAGAGTGGGGCTTTGC-3′ ; ulk1-rev, 5′ -GCCCTGGCAGGATACCACGC-3′ ; atg7-fw, 5′ -CCGGTGGCTTCC TACTGTTA-3′ ; atg7-rev, 5′ -AAGGCAGCGTTGATGACC-3′ . Chromatin immunoprecipitation with sequencing data analysis. Peak calling was performed using model-based analysis of chromatin immunoprecipitation with sequencing (ChIP-seq) (MACS) 35 with Galaxy Tool Version 1.0.1 35 . P-value cutoff for peak detection was selected as ≤ 10 −5 , and the false discovery rate as ≤ 0.05. Promoter motif analysis. Regions that are 2,000 bp upstream and 100 bp downstream from the transcription start sites of Becn1, Atg7, Ulk1 and Ulk3 were scanned using the mouse (mm10) genome annotation using the HOMER v4.9.1 findMotifs.pl script with start = − 2,000 and end = 100 and a log odds-score threshold of 5, looking for the motif 'GTAGGTCACTGGGTCA' and trained on data from a previous study 36 . Lipid extraction. Lipid extraction was performed as previously described 37, 38 . A172 cells were vortexed for 30 s in a mixture of 1:1:2 PBS:methanol:chloroform. A 13 C 16 -palmitic acid standard (200 pmol per sample) was added to chloroform before extraction. The resulting mixture was centrifuged at 2,200 g, 5 min, 4 °C to separate organic and aqueous phases. The organic phase (bottom layer) was collected and dried under a stream of nitrogen. Lipidomic analysis. Lipidomic analysis was performed as previously described 39 . In brief, a Bio-Bond 5U C4 column (Dikma) was used to achieve separation of lipids. The liquid chromatography solvents were as follows: buffer A, 95:5 H 2 O:methanol + 0.03% NH 4 OH; buffer B, 60:35:5 isopropanol: methanol:H 2 O + 0.03% NH 4 OH. A typical liquid chromatography run consisted of the following for 70 min after injection: 0.1 ml min −1 100% buffer A for 5 min, 0.4 ml min −1 linear gradient from 20% buffer B to 100% buffer B over 50 min, 0.5 ml min −1 100% buffer B for 8 min and equilibration with 0.5 ml min −1 100% buffer A for 7 min. Lipidomic analysis was performed using a Thermo Fisher Scientific Q Exactive Plus fitted with a heated electrospray ionization source in negative ionization mode. The MS source parameters were 4-kV spray voltage, with a probe temperature of 437.5 °C and capillary temperature of 268.75 °C. Fullscan mass spectrometry data was collected at a resolution of 70 k, automatic gain control target 1 × 106, maximum injection time of 100 ms and a scan range of 150-2,000 m/z. Data-dependent mass spectrometry (top 5 mode) was acquired at a resolution of 35 k, automatic gain control target 1 × 105, maximum injection time of 50 ms, isolation window 1 m/z, scan range 200-2,000 m/z and a stepped normalized collision energy of 20, 30 and 40. Extracted ion chromatograms for each lipid were generated using a threshold of 5 p.p.m. around the molecular anion [M− H] − exact mass. Lipids, acyl chain composition and degree of unsaturation were validated by analysing the product ions in the corresponding tandem mass spectra. Relative quantification of lipids was performed by measuring the area under the peak and dividing this number by the area under the peak for the internal standard 13 C 16 -palmitatic acid.
In vivo experiments. Mice were purchased from The Jackson Laboratories. All the colonies were bred as indicated by Jackson Laboratories and maintained in pathogen-free conditions at The Salk Institute, except NOD.Cg-Prkdc scid Il2rg tm1Wjl / SzJ mice, which were maintained at The University of Texas MD Anderson Cancer Center and Tyr-Nras Q61K mice and their wild-type counterparts, which were maintained at the University of California, Irvine. C57BL/6J, NOD. Cg-Prkdc scid Il2rg tm1Wjl /SzJ and Tyr-Nras Q61K 3-14-week-old male and female mice were used. No statistical methods were used to predetermine sample size but it was determined according to previous experi mental observations. All the procedures performed in this study were approved by the Institutional Animal Care and Use Committee of the SALK institute, the University of California, Irvine and the University of Texas MD Anderson Cancer Center. In all experiments, mice were monitored daily for signs of illness and were euthanized when they reached endpoints. The 005 cells (5 × 10 4 cells per 1.5 μ l) or GSC 8.11 cells (1.5 × 10 5 per 1.5 μ l) were stereotaxically injected into anaesthetized 8-16-week-old mice (C57BL/6J for 005 cells, and NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ for GSCs). The following coordinates were used: subventricular zone, 1.5 mm, 2.0 mm and 2.3 mm; hard palate, 2.0 mm, 1.5 mm and 2.3 mm; cerebral cortex, 1 mm, 1 mm, and 0.5 mm or 1.0 mm; 0 mm, 1 mm and 0.5 mm or 1.0 mm; and 2.0 mm, 1.5 mm and 0.5 mm; striatum, 0 mm, 1.4 mm and 3.0 mm (all measurements are posterior, lateral and dorsal to the bregma, respectively). To ensure that each experimental group had an equivalent starting tumour, after tumour sizes were quantified by magnetic resonance imaging mice were divided into two groups (vehicle and SR9009) and three weeks after injection, the treatment was started. Similarly, NOD.Cg-Prkdc scid Il2rg tm1Wjl / SzJ mice were imaged by bioluminescence imaging and after tumour sizes were quantified they were divided in two (vehicle and SR9009) or three groups (vehicle, SR9009 and temozolomide). The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment.
For all bioluminescence imaging, d-luciferin (150 mg kg −1 ) was administered by subcutaneous injection to mice 10 min before imaging. Mice were fed with Picolab Diet 20 No. 5058. SR9009 was administered twice per day by intraperitoneal injection at the indicated concentrations for one week, and on subsequent days once a day unless otherwise stated. Temozolomide was administered once per day by intraperitoneal injection at 82.5 mg kg −1 for 5 days. All mice in this study were kept according to guidelines approved by the Animal Care and Use Committee of the Salk Institute. For the naevi studies, both ears of Tyr-Nras Q61K and wildtype littermate mice at postnatal day 21 were treated with SR9009 or DMSO. Forty microlitres of drug SR9009 at 20 μ M diluted with DMSO was applied to each ear twice daily for twelve consecutive days. Mice were killed one hour after the final treatment. Four mice (eight ears) were used in each group. Statistical analysis. Results are shown as means ± s.d. or s.e.m., as indicated in the figure legends. P values were calculated as indicated in figure legends, with 95% confidence level. Data availability. All data and reagents are available from the authors upon reasonable request. All gel source data are available in Supplementary Fig. 1 . Tumour source data ( Fig. 4f and Extended Data Fig. 9d , i) are available as Source Data; ChIP-seq data 5 and The Cancer Genome Atlas data 30, 31 have previously been published.
Extended Data Figure 2 | Induction of apoptosis by agonists of REV-ERBs is independent of p53 and oxidative stress. a-j, Treatment with agonists of REV-ERBs triggers apoptosis independently of p53 status, as shown by proliferation assay (7 days, 20 μ M; a, c, f, h) and TUNEL assay (3 days, 20 μ M; b, i, j) in cancer cell lines affected by various types of p53 alteration. n indicates biologically independent samples; T47D, n = 8 (mock), n = 6 (SR9009) and n = 10 (SR9011), one-way ANOVA, * * * * P < 0.0001; PANC-1, n = 4 (mock), n = 6 (SR9009) and n = 7 (SR9011), one-way ANOVA; TUNEL assay, * P = 0.0108; cleaved caspase 3, * * * * P < 0.0001; SKMEL28, n = 4 (mock), n = 5 (SR9009, SR9011), one-way ANOVA; TUNEL assay, * * * * P < 0.0001; cleaved caspase 3, * * P = 0.0035. d, e, Apoptosis is induced in both wild-type and p53-null HCT116 cells (TUNEL assay, 4 days, 20 μ M, mean ± s.e.m.). One-tailed Mann-Whitney test. n indicates biologically independent samples. HCT116 wild type, n = 5 (mock, SR9009), * * P = 0.004; HCT116 p53 knockout, n = 8 (mock) or 6 (SR9009), * * * P = 0.0003. f, Immunoblot analysis of cleaved caspase 3 shows that agonists of REV-ERBs trigger apoptosis in the RIGH cell line (one experiment). k, Co-treatment with the reducing agent NAC (10 mM) does not rescue the viability of A375 cells (20 μ M, 7 days). n indicates biological replicates, n = 5 (mock, − NAC) or 6 (all other dot plots). One-way ANOVA, * * * * P < 0.0001. l, Results obtained under hypoxic conditions (20 μ M, 6 days) were similar to those obtained in co-treatments with NAC. n indicates biological replicates, n = 3 (mock − NAC, mock hypoxia and SR9009 hypoxia) or 6 (SR9009 normoxia, SR9011 normoxia and SR9011 hypoxia). One-way ANOVA, * * * * P < 0.0001). m, n, Hypoxia or co-treatment with NAC does not alter the ability of agonists of REV-ERBs to induce apoptosis in A375 cells. One-way ANOVA. n indicates biologically independent samples: normoxia, n = 3 (mock), n = 5 (SR9009) or n = 11 (SR9011); TUNEL assay, * P = 0.0432; cleaved caspase 3, * * * P = 0.0004; hypoxia, n = 6 (mock), n = 13 (SR9009) or n = 14 (SR9011); TUNEL assay, * * * P = 0.0005; cleaved caspase 3, * P = 0.0028; NAC, n = 3 (mock), n = 4 (SR9009) or n = 3 (SR9011); TUNEL assay, * P = 0.0104; cleaved caspase 3, * * P = 0.0042. Scale bars, 50 μ m. All panels representative of three biologically independent experiments with similar results unless otherwise specified. All data are mean ± s.e.m. Norm, normoxia; Hypo, hypoxia. For gel source data, see Supplementary Fig. 1 . (mock ± NAC), n = 6 (SR9009/SR9011 ± NAC), n = 9 (SR9009 + NAC), n = 11 (SR9011 + NAC), n = 3 (mock normoxia), n = 6 (SR9009/SR9011 normoxia and hypoxia), n = 5 (mock hypoxia) 6 days, one-way ANOVA, * * * * P < 0.0001. c, d, Apoptosis induction of HCT116 cells remained unchanged under hypoxia or on co-treatment with NAC; 20 μ M, 6 days, one-way ANOVA. n indicates biologically independent samples: normoxia, n = 5 (mock), n = 6 (SR9009), n = 8 (SR9011); TUNEL assay, * * * P = 0.0003; cleaved caspase 3, * * P = 0.0021; hypoxia, n = 3 (mock), n = 5 (SR9009), n = 4 (SR9011); TUNEL assay, * * P = 0.0015; cleaved caspase 3, * * P = 0.0046; NAC, n = 4 (mock), n = 5 (SR9009), n = 5 (SR9011); TUNEL assay, * * * * P < 0.0001; cleaved caspase 3, * * * * P < 0.0001. e, In MCF-7 cells, apoptosis triggered by agonists of REV-ERBs is independent of oxidative state, as shown by proliferation assay (20 μ M). n indicates biological replicates: n = 6 (mock, normoxia and hypoxia), n = 4 (09-011 normoxia), n = 7 (09 hypoxia), n = 5 (011 hypoxia); one-way ANOVA, * * * * P < 0.0001; f, g TUNEL assay and immunofluorescence analysis of cleaved caspase 3 confirm previous results (Extended Data Fig 3c, d) . n indicates biologically independent samples. n = 3 (mock normoxia), n = 5 (mock hypoxia), n = 11 (09 normoxia), n = 8 (09 hypoxia), n = 10 (011 normoxia and hypoxia). One-way ANOVA. Normoxia, TUNEL assay, * * P = 0.0049; cleaved caspase 3,* * P = 0.0054; hypoxia, TUNEL assay, * * * * P < 0.0001; cleaved caspase 3, * * * * P < 0.0001. All panels representative of three biologically independent experiments with similar results. All data are mean ± s.e.m. Norm, normoxia; Hypo, hypoxia. 
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Extended Data Figure 10 | SR9009 impairs tumour growth and improves survival of glioblastoma patient-derived xenografts. a, Protein levels of autophagy genes in NRAS naevi are reduced upon treatment with SR9009, as assayed by immunoblot (n = 4 mice, one experiment). b, TUNEL assays show that apoptosis induction is absent in normal skin on treatment with SR9009 (n = 4 mice, one experiment, 12 days, SR9009 20 μ M). Scale bar, 10 μ m; BF, bright field. c, TUNEL assays show that apoptosis induction is absent in normal brain tissues on treatment with SR9009 (6 days, 200 mg kg −1 twice a day, n = 5 mice, one experiment). d, Treatment with SR9009 (100 mg kg −1 twice a day) is tolerated better than temozolomide administration (82.5 mg kg −1 once a day for 5 days), as shown by measurement of percentage body weight change. One-tailed Mann-Whitney test; day 6, 8, 10, * P = 0.0411, mean ± s.e.m. n = 5 (SR9009) or 6 (temozolomide) mice. e, The glioblastoma cell line A172 is sensitive to treatment with SR9009 and SR9011 (20 μ M 6 days, three biologically independent experiments with similar results). f, Previous analyses 30 of The Cancer Genome Atlas data show genetic alterations that affect NR1D1 and NR1D2 are absent. Gene expression analysis shows that no cases are present with downregulation of REV-ERBs, and only a small fraction with upregulation. n = 574 biologically independent samples. NR1D1: upregulation, 1.56%; homozygous deletion (Hom Del), 0.17%; unaltered, 98.27%. NR1D2: upregulation, 4.54%; unaltered, 95.46%. g, In vivo treatment with SR9009 results in the decrease of ATG7 protein levels (6 days, 200 mg kg −1 twice a day, n = 5 mice, one experiment). h, SR9009 treatment impairs in vivo growth of glioblastoma patient-derived xenografts (6 days, 200 mg kg −1 , n = 5 mice). i, Quantification of tumour size by in vivo luciferase assays (mean ± s.e.m., n = 10 mice, one-tailed Mann-Whitney test, * * P = 0.0057). j, SR9009 improves survival in mice that bear glioblastoma patient-derived xenografts. SR9009 200 mg kg −1 twice a day, n = 11 (vehicle), n = 11 (SR9009), n = 11 (temozolomide (82.5 mg kg −1 once a day for 5 days)) mice; two-tailed log-rank analyses. For gel source data, see Corresponding author(s): Satchidananda Panda, Gabriele Sulli
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Replication
Describe whether the experimental findings were reliably reproduced.
Yes the experimental findings were reliably reproduced as described in the figure legends
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
In order to ensure that each experimental group had an equivalent starting tumor size either MRI or in vivo BLI were used in order to separate the mice into the experimental groups before treatment. No reasons to randomize experiments for this study
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
No blinding
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
